Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 50,434 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Clear all

Conditions: Colorectal Cancer, Minimal Residual Disease
Interventions: Fludarabine Phosphate, Cyclophosphamide, Cetuximab, TROP2-CAR-NK Cells, Rimiducid (AP1903), Lymphodepleting Chemotherapy; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer
Interventions: bevacizumab, cisplatin, conventional surgery, intensity-modulated radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Rectal Cancer
Interventions: CT Virtual Proctoscopy (CTVP); Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Glioblastoma Multiforme, Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Renal Cell Carcinoma
Interventions: DSP-7888 Dosing Emulsion; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 8
States / cities: Denver, Colorado • Atlanta, Georgia • Lafayette, Indiana + 5 more

Conditions: Cancer, Cardiovascular Diseases, Hereditary Cancer, Hereditary Cardiac Amyloidosis
Interventions: e-Health (web-based) disclosure portal, Provider mediated disclosure; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Parents Who Have Lost a Child to Cancer
Interventions: Questionnaires/Interviews; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2027
U.S. locations: 2
States / cities: Bethesda, Maryland • New York, New York

Conditions: Metastatic Malignant Melanoma
Interventions: Temozolomide and SU11248; Drug
Lead sponsor: Northern California Melanoma Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Lymphocytic Leukemia
Interventions: Biospecimen Collection; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: oxaliplatin; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more

Conditions: Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions: Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Polycystic Ovary Syndrome, Hypertension
Interventions: GnRH antagonist, GnRH antagonist + MethylTESTOSTERone 5 MG; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Endometrial Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms, Genital Neoplasms, Female
Interventions: Psychosocial; Behavioral
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 20 Years to 75 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Columbus, Ohio

Conditions: Lipoma
Interventions: Cooled Sodium Chloride Injection, Warmed Sodium Chloride Injection; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Wound Healing After MMS Surgery, BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Melanoma In Situ
Interventions: A microsurfaced ADM (acellular dermal matrix); Device
Lead sponsor: McGuire Institute; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rockwall, Texas

Conditions: Smoldering Multiple Myeloma
Interventions: Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone; Drug
Lead sponsor: International Myeloma Foundation; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 10
States / cities: Tampa, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
Interventions: revumenib, cobicistat; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 30 Days and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 22
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 17 more

Conditions: Stage I Breast Carcinoma, Stage II Breast Carcinoma
Interventions: intra-operative MRI; Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Melanoma
Interventions: TLPLDC, Placebo; Drug
Lead sponsor: Elios Therapeutics, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 15 more

Conditions: Non Small Cell Lung Cancer
Interventions: Pazopanib, Erlotinib; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 8
States / cities: Fort Myers, Florida • Lawrenceville, Georgia • Cincinnati, Ohio + 5 more

Conditions: Leukemia
Interventions: aldesleukin; Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 104
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 77 more

Conditions: Breast Cancer
Interventions: Mammography; Radiation
Lead sponsor: Lunit Inc.; Industry
Eligibility: Female only
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pancreatic Neoplasms
Interventions: PEP02; Drug
Lead sponsor: PharmaEngine; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lymphedema
Interventions: Strength training; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 295 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions: Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride, Paclitaxel, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 431
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 298 more

Search by objective public record fields.

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

CT Virtual Proctoscopy for Staging and Volume Assessment for Rectal Cancer

A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies

Penn Biobank Return of Research Results Program

Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer

Temodar and Sutent as Therapy for Melanoma

Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab

Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma

Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome

Questionnaire Study for Gynecological Cancer Survivors

Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride

Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Image-guided Breast Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)

Phase IIB TL + YCWP + DC in Melanoma

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia

Study to Evaluate Effectiveness of Investigational Device in the Assistance of Detection and Diagnosis of Breast Cancer

Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer

Strength Training Intervention for Breast Cancer Survivors and the Effects on Lymphedema Status

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer